Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

Science Translational Medicine
Siwen Hu-LieskovanAntoni Ribas

Abstract

Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the high response rates of targeted therapy and the durability of responses with immunotherapy. However, the first clinical trial testing the combination of the BRAF inhibitor vemurafenib and the CTLA4 antibody ipilimumab was terminated early because of substantial liver toxicities. MEK [MAPK (mitogen-activated protein kinase) kinase] inhibitors can potentiate the MAPK inhibition in BRAF mutant cells while potentially alleviating the unwanted paradoxical MAPK activation in BRAF wild-type cells that lead to side effects when using BRAF inhibitors alone. However, there is the concern of MEK inhibitors being detrimental to T cell functionality. Using a mouse model of syngeneic BRAF(V600E)-driven melanoma, SM1, we tested whether addition of the MEK inhibitor trametinib would enhance the antitumor activity of combined immunotherapy with the BRAF inhibitor dabrafenib. Combination of dabrafenib and trametinib with pmel-1 adoptive cell transfer (ACT) showed complete tumor regression, increased T cell infiltration into tumors, and improved in vivo cytotoxicity. Single-agent dabrafenib increased tumor-associated macrophages and T regulatory c...Continue Reading

References

Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Aug 20, 2003·The Journal of Experimental Medicine·Willem W OverwijkNicholas P Restifo
Feb 13, 2004·Bioinformatics·Laurent GautierRafael A Irizarry
Oct 6, 2004·Genome Biology·Robert C GentlemanJianhua Zhang
Jun 28, 2006·The Journal of Experimental Medicine·Hidetoshi SumimotoYutaka Kawakami
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adil I DaudDmitry Gabrilovich
Oct 4, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Je-In YounDmitry I Gabrilovich
Feb 7, 2009·Nature Reviews. Immunology·Dmitry I Gabrilovich, Srinivas Nagaraj
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jul 6, 2010·BMC Bioinformatics·Renaud Gaujoux, Cathal Seoighe
Dec 21, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Begoña Comin-AnduixAntoni Ribas
Feb 1, 2011·Annals of the New York Academy of Sciences·Brian T Fife, Kristen E Pauken
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Dec 14, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James S WilmottRichard A Scolyer
Jan 5, 2012·Cancer Immunology, Immunotherapy : CII·Matthew R PorembkaPeter Goedegebuure
Jan 20, 2012·The New England Journal of Medicine·Fei SuRichard Marais
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Oct 26, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaofeng JiangF Stephen Hodi
Dec 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chengwen LiuPatrick Hwu
Dec 19, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Linda WangKhoon Lin Ling
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dennie T FrederickJennifer A Wargo
Mar 5, 2013·The Journal of Clinical Investigation·Deborah A KnightMark J Smyth
Mar 12, 2013·The Journal of Investigative Dermatology·Jinhua WangDave S B Hoon
Mar 14, 2013·Oncoimmunology·Bishu SapkotaBrian P Pollack
Apr 5, 2013·The New England Journal of Medicine·Antoni RibasJedd Wolchok
Apr 6, 2013·Pigment Cell & Melanoma Research·Georgina V LongRichard F Kefford
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 14, 2013·Oncoimmunology·Zachary A CooperJennifer A Wargo
Jun 7, 2014·Cancer Immunology Research·Zachary A CooperJennifer A Wargo
Jun 25, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Siwen Hu-LieskovanAntoni Ribas

❮ Previous
Next ❯

Citations

Jul 25, 2015·Expert Opinion on Biological Therapy·Martina SanlorenzoDario Sangiolo
Jan 26, 2016·Cancer Cell·Shinichi YachidaTatsuhiro Shibata
Jan 28, 2016·Scientific Reports·Simon Chang-Hao TsaoMatt Trau
Apr 12, 2016·Frontiers in Cell and Developmental Biology·Paul C McDonaldShoukat Dedhar
Apr 6, 2016·Future Oncology·Kimberly M KomatsubaraRichard D Carvajal
May 4, 2016·Oncoimmunology·Jessica C HasselAlexander H Enk
Apr 14, 2016·Expert Review of Clinical Immunology·Andrea GuennounDavide Bedognetti
Jun 22, 2016·Expert Opinion on Drug Discovery·Alex Kim, Mark S Cohen
Jun 24, 2016·British Journal of Cancer·Shivshankari Rajkumar, Ian R Watson
Jul 28, 2016·Current Treatment Options in Oncology·Kim Margolin
Sep 11, 2016·Current Oncology Reports·Kevin Wood, Jason J Luke
Apr 29, 2016·BJU International·Jennifer M Mataraza, Philip Gotwals
Oct 22, 2016·ACS Chemical Biology·Michael GrassoRonen Marmorstein
Dec 20, 2016·Laboratory Investigation; a Journal of Technical Methods and Pathology·Mario MandalàDaniela Massi
Apr 9, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Annie N M WongRodney J Hicks
Jan 22, 2017·Experimental Dermatology·Nikolas K Haass, Brian Gabrielli
Feb 12, 2017·Cell·Padmanee SharmaAntoni Ribas
Jan 24, 2017·The Cancer Journal·Shelly A ChristiansenGeoffrey T Gibney
Jan 18, 2017·Pigment Cell & Melanoma Research·Nicola ThompsonMarco Ranzani
Apr 7, 2017·Pediatric Blood & Cancer·John Anderson
Jan 1, 2016·Journal of the National Cancer Institute·Anna E VilgelmAnn Richmond
Feb 28, 2018·Journal of Hematology & Oncology·Xiaolei LiWeidong Han
Jun 21, 2017·International Journal of Molecular Sciences·Ying-Ying LiNiramol Savaraj
Sep 2, 2017·American Journal of Clinical Dermatology·Alice Y Zhou, Douglas B Johnson
Feb 8, 2018·Frontiers in Oncology·Taku FujimuraSetsuya Aiba
Apr 20, 2017·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jae Young JoungYoung-Joo Won
Jan 12, 2016·Therapeutic Advances in Medical Oncology·Zeynep Eroglu, Antoni Ribas
Jul 19, 2018·Journal of Occupational and Environmental Medicine·Kristine Krajnak, Stacy Waugh
Mar 15, 2016·F1000Research·Laura GayTrevor A Graham
Oct 24, 2018·Biological Chemistry·Elena ObradorJosé M Estrela
Feb 20, 2018·Molecular Cancer·Wagner Ricardo MontorFabiana Henriques Machado de Melo
Apr 13, 2019·Expert Opinion on Drug Safety·Kristy Kummerow BromanJonathan S Zager
May 18, 2019·American Society of Clinical Oncology Educational Book·Charlene M FaresSiwen Hu-Lieskovan
Nov 18, 2017·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Liang ChengRodolfo Montironi
Jun 7, 2019·Nature Medicine·Ryan J SullivanPatrick Hwu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.